Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Aegerion, QLT merge to form Novelion

by Lisa M. Jarvis
June 20, 2016 | A version of this story appeared in Volume 94, Issue 25

Beleaguered Aegerion Pharmaceuticals will merge with a subsidiary of QLT to form a rare disease-focused company named Novelion Therapeutics. A group of investors will sink roughly $22 million into QLT, bringing Novelion’s total cash to more than $100 million. Novelion’s portfolio will include two approved drugs—Aegerion’s Juxtapid, a treatment for a rare form of high cholesterol, and the leptin analogue Myalept—and QLT’s drug for rare eye diseases, which is on the cusp of Phase III studies. In February, Aegerion laid off 25% of its workforce after the arrival of competitors to Juxtapid.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.